Experimental COVID-19 drug shows promise in tiny trial
NCT ID NCT04534673
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether adding pegylated interferon lambda to standard care helps hospitalized adults with mild-to-moderate COVID-19 recover faster. Nine participants were randomly assigned to receive the drug or standard care alone. The study measured how long the virus remained detectable and how quickly symptoms improved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pegylated interferon lambda
- What this could lead to
- If it works, this could point toward a treatment that shortens COVID-19 symptoms and reduces the need for breathing support.
- What could go wrong
- This is a very small pilot trial with only 9 participants, so results may not apply to the general population. The drug may not speed recovery or reduce complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Soroka UMC
Beersheba, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?